Loginx

If you have an account with us, please log in.

Create an AccountForgot Your Password?

* Required Fields

Create an Accountx

* Required Fields

Back to Login

Forgot Your Password?x

Please enter your email address below. You will receive a link to reset your password.

* Required Fields

Back to Login

PDGFR

Target
  1. VEGFR2 (1)
Actions
  1. Inhibitor (15)


18 Item(s)

per page

Set Descending Direction
Catalog No. Product Name Product Information
A15933

AC710

AC710 is a potent, orally active, and selective platelet-derived growth factor receptor-family kinase inhibitor with potential anticancer activity. Learn More
A11350

CP-673451

CP 673451 is a potent PDGFR-β inhibitor with an IC50 of 1 nM. Learn More
A11052

Crenolanib (CP-868596)

Crenolanib (CP-868596) is an orally bioavailable, selective small molecule inhibitor of the PDGFR tyrosine kinase, inhibiting both PDGFRA and PDGFRB at picomolar concentrations. Learn More
A15062

DCC-2618

DCC-2618 is a small molecule inhibitor of c-Kit and PDGFR with IC50s of 6 nM/30 nM/13 nM for c-Kit/PDGFR??/PDGFR?? respectively. Learn More
A11978

Delphinidin chloride

Delphinidin chloride is an anthocyanidin, a common plant pigment, found in pigmented fruits and vegetable. Learn More
A13530

Flumatinib mesylate

Flumatinib mesylate can reduce the expression of C-MYC, HIF-1 a and VEGF in U266 cell line in a time- and dose-dependent manners, so flumatinib mesylate may become a new drug for MM therapy. Learn More
A10504

KRN 633

KRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor that inhibits PDGFR-α and c-Kit at higher concentrations only (IC50 = 0.97 μM and 4.33 μM, respectively) and inactive towards 17 other kinases (IC50 ≥ 10 μM). Learn More
A10025

Linifanib (ABT-869)

Linifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-β, KDR, and CSF-1R, respectively. Learn More
A15152

Masitinib mesylate

Masitinib mesylate is a novel inhibitor for Kit and PDGFR??/?? with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms. Learn More
A11753

MK-2461

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Learn More
A15182

N-Desethyl Sunitinib

N-desethyl sunitinib is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFR?? and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFR?? and KIT respectively). Learn More
A10699

Pazopanib HCl (GW786034)

Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis. Learn More
A11518

Pazopanib(GW-786034)

Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis. Learn More
A13111

R1530

R1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta? FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2. Learn More
A10250

Regorafenib (BAY 73-4506)

Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature. Learn More
A10880

Sunitinib Malate

Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Learn More
A10903

Telatinib (BAY 57-9352)

Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases. Learn More
A11581

Toceranib (PHA 291639, SU 11654)

Toceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ. Learn More

18 Item(s)

per page

Set Descending Direction
PDGFR

Minimal Price: $32.00